Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Technical Presentation (March 2017)

13 slides from Aevi Genomic Medicine's technical presentation, Mar 20, 2017

  1. Slide 1: AEVI-001: SAGA Trial in mGluR+ ADHD Topline Results

    © 2017, Aevi Genomic Medicine AEVI - 001: SAGA Trial in mGluR + ADHD Topline Results March 20, 2017

  2. Slide 2: Forward-Looking Statement

    © 2017, Aevi Genomic Medicine 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financi

  3. Slide 3: SAGA Trial Summary

    © 2017, Aevi Genomic Medicine 3 SAGA Trial Summary • Trial did not meet primary endpoint (overall ADHD - RS) 1 , however showed encouraging trend in improvement at highest dose (400 mg BID) – Strong trend of efficacy in ADHD - RS inattention subscale (p=0.0515 vs placebo) • Clear signal of efficacy

  4. Slide 4: A Novel Paradigm of Diagnosis and Treatment in Neuropsychiatric Diseases

    © 2017, Aevi Genomic Medicine 4 A Novel Paradigm of Diagnosis and Treatment in Neuropsychiatric Diseases • Novel genomic discovery identifies disruptive mutations in the mGluR network in a significant subpopulation (20 - 25%) of ADHD patients – Role of glutamate in ADHD is supported by recent geneti

  5. Slide 5: AEVI-001: A glutamate signaling modulator

    © 2017, Aevi Genomic Medicine 5 AEVI - 001 A glutamate signaling modulator • Oral non - stimulant • Originator : Nippon Shinyaku • MOA : Pan - selective activator/modulator of mGluRs that modulates glutamatergic signaling restoring homeostasis 1,2 • Excellent PK/metabolic profile • Crosses blood - b

  6. Slide 6: SAGA Trial Design in mGluR+ Adolescents

    © 2017, Aevi Genomic Medicine 6 SAGA Trial Design in mGluR + Adolescents *Elia et al. (2012) Nat Genet , 44(1):78 - 84 • Multicenter (24 sites) • Inclusion criteria: – Adolescents (12 - 17 years of age) – ADHD - RS - 5 ≥ 28 – Positive for mGluR mutation – Investigators, patients and parents were not

  7. Slide 7: Patient Demographics

    © 2017, Aevi Genomic Medicine 7 Patient Demographics Parameter AEVI - 001 (n=46) Placebo (n=50) Age Mean (SD) 13.8 (1.40) 14.4 (1.68) Gender Male Female 26 (55%) 20 (45%) 35 (70%) 15 (30%) ADHD - RS - 5 Total Score at Baseline Mean (SD) 36.8 (6.88) 38.6 (7.23) CGI - S Score at Baseline Mean (SD) 4 -

  8. Slide 8: Change in ADHD-RS Score from Baseline Over Time

    © 2017, Aevi Genomic Medicine 8 B a s e l i n e W e e k 1 ( 1 0 0 m g B I D ) W e e k 2 ( 2 0 0 m g B I D ) W e e k 3 ( 4 0 0 m g B I D ) W e e k 4 ( O p t i m i z e d D o s e ) W e e k 5 ( M a i n t e n a n c e D o s e ) W e e k 6 ( M a i n t e n a n c e D o s e ) -20 -15 -10 -5 0 C h a n g e i n A

  9. Slide 9: Clinically and Statistically Significant Response Rate (ADHD-RS Reduction >30%)

    © 2017, Aevi Genomic Medicine 9 W e e k 1 ( 1 0 0 m g B I D ) W e e k 2 ( 2 0 0 m g B I D ) W e e k 3 ( 4 0 0 m g B I D ) W e e k 4 ( O p t i m i z e d D o s e ) W e e k 5 ( M a i n t e n a n c e D o s e ) W e e k 6 ( M a i n t e n a n c e D o s e ) 0 20 40 60 80 P e r c e n t a g e o f p a t i e n

  10. Slide 10: Clinically and Statistically Significant Response (CGI-I of 1 or 2) at Week 6

    © 2017, Aevi Genomic Medicine 10 W e e k 1 ( 1 0 0 m g B I D ) W e e k 2 ( 2 0 0 m g B I D ) W e e k 3 ( 4 0 0 m g B I D ) W e e k 4 ( O p t i m i z e d D o s e ) W e e k 5 ( M a i n t e n a n c e D o s e ) W e e k 6 ( M a i n t e n a n c e D o s e ) 0 20 40 60 P e r c e n t a g e o f p a t i e n t

  11. Slide 11: AEVI-001: Safety and Tolerability

    © 2017, Aevi Genomic Medicine 11 AEVI - 001: Safety and Tolerability • AEVI - 001 was well - tolerated; 88% achieved highest dose of 400 mg BID • No serious adverse events • Majority of AEs judged to be mild or moderate AEVI - 001 Placebo Number of subjects with ≥1 AE 33/47 (70.2%) 28/50 (56%) AEs >

  12. Slide 12: AEVI-001: Next Steps

    © 2017, Aevi Genomic Medicine 12 AEVI - 001: Next Steps • Enrich ADHD study population to enhance response rate and effect size: – Refine responders using genomic biomarker – Higher exposure: dose and duration – Pediatric (ages 6 - 12) ADHD study: – Higher responses, better compliance, lower placebo

  13. Slide 13: Thank you

    © 2017, Aevi Genomic Medicine 13 Thank you

Aevi Genomic Medicine — Technical Presentation (March 2017) on 6ix